CN116008559A - Application of MCM6 as pathological prognosis marker of EMZL distant recurrence - Google Patents
Application of MCM6 as pathological prognosis marker of EMZL distant recurrence Download PDFInfo
- Publication number
- CN116008559A CN116008559A CN202211579996.7A CN202211579996A CN116008559A CN 116008559 A CN116008559 A CN 116008559A CN 202211579996 A CN202211579996 A CN 202211579996A CN 116008559 A CN116008559 A CN 116008559A
- Authority
- CN
- China
- Prior art keywords
- mcm6
- lymphoma
- prognosis
- detecting
- emzl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to an application of MCM6 as a pathological prognosis marker for EMZL distant recurrence, belonging to the technical field of biological medicine. The invention provides a method for obtaining the prognosis information of the lymphoma at the outer edge area of the junction, and the prognosis information of the lymphoma at the outer edge area of the junction is predicted by detecting the MCM6 expression quantity. Provides an application of a reagent for detecting MCM6 in preparing a node outer edge zone lymphoma prognosis diagnosis kit. A diagnostic kit for prognosis of a node outer edge region lymphoma is provided for predicting whether a node outer edge region lymphoma recurs far. The invention obtains a pathological prognosis biomarker MCM6 capable of predicting the distant recurrence of an EMZL patient through screening proteomic sequencing data, wherein MCM6 is a specific high-expression protein for the distant recurrence of the EMZL, can be used as a pathological marker of the EMZL prognosis, and is used for guiding risk stratification and treatment decision of the patient.
Description
Technical Field
The invention relates to an application of MCM6 as a pathological prognosis marker for EMZL distant recurrence, belonging to the technical field of biological medicine.
Background
The external junction border zone lymphoma (EMZL) responds well to radiotherapy with a higher overall survival rate, but distant recurrence of disease is a critical issue in EMZL treatment. The clinical risk factors related to remote relapse require a clinician to comprehensively judge by combining medical history, clinical symptom signs and imaging characteristics, and have certain subjectivity. The pathological features have stronger objectivity than the clinical features. At present, the proportion of Ki-67 IHC staining positive cells is clinically used as an EMZL poor prognosis reference, but no related study is used for verifying the effectiveness of the cells in EMZL; therefore, EMZL lacks disease-specific prognostic-related pathological markers; the technical problem of how to more effectively perform prognosis of distant recurrence of EMZL is needed to be solved in the technical field.
Disclosure of Invention
The invention aims to solve the technical problem of how to more effectively carry out prognosis judgment of EMZL distant recurrence.
In order to solve the above problems, the technical solution adopted by the present invention is to provide a method for obtaining prognosis information of lymphoma in the outer edge region of a junction, which comprises predicting the prognosis information of lymphoma in the outer edge region of the junction by detecting the MCM6 expression level.
Preferably, the prognostic information is a prediction of whether or not the node outer border region lymphoma is distant in recurrence.
The invention provides an application of a reagent for detecting MCM6 in preparing a node outer edge zone lymphoma prognosis diagnosis kit.
Preferably, the prognosis in the application is predictive of whether or not the node outer edge zone lymphoma is distant to recurrence.
The invention provides a diagnostic kit for prognosis of junction peripheral zone lymphoma, wherein the kit comprises a reagent for detecting MCM 6.
Preferably, the diagnostic kit is used to predict whether a node outer edge region lymphoma recurs far.
The invention provides a detection system, which comprises a data processing device and a substance for detecting MCM 6; the data processing device comprises a data input module, a data recording module, a data comparison module and a conclusion output module; the data input module is configured to input an expression value of a sample MCM6 to be tested; the data recording module is configured to store the expression value and the judgment threshold value of the MCM6 of the sample to be tested; the data comparison module is configured to receive the expression magnitude of the to-be-detected sample MCM6 sent by the data input module, call the judgment threshold value from the data recording module and compare the judgment threshold value with the expression magnitude of the to-be-detected sample MCM 6; the conclusion output module is configured to receive the comparison result sent by the data comparison module and judge the comparison result according to a preset judgment condition; determining whether the lymphoma in the outer edge zone of the junction of the tested person recurs far.
Preferably, the means for detecting MCM6 comprises reagents and/or instrumentation for detecting the amount of expression of MCM 6.
Compared with the prior art, the invention has the following beneficial effects:
according to the invention, a pathological biomarker MCM6 capable of predicting the distant recurrence of an EMZL patient is obtained through screening proteomic sequencing data, and MCM6 is a specific high-expression protein for the distant recurrence of the EMZL, can be used as a pathological marker for the prognosis judgment of the EMZL, and is used for guiding risk stratification and treatment decision of the patient.
Drawings
FIG. 1 is a MCM6 screening flow chart and differential gene expression scatter plot;
FIG. 2 is a graph showing H-score comparison of relative expression of MCM6 and Ki-67 in distant relapse groups.
FIG. 3 is a graph showing the results of the predictive power of distant recurrence of MCM6 and Ki-67.
Detailed Description
In order to make the invention more comprehensible, preferred embodiments accompanied with the accompanying drawings are described in detail as follows:
as shown in fig. 1-3; the invention provides a method for obtaining prognosis information of lymphoma at the outer edge area of a junction, which comprises the steps of predicting the prognosis information of lymphoma at the outer edge area of the junction by detecting the MCM6 expression quantity; the prognosis information is used for predicting whether the lymphoma in the outer edge zone of the junction recrudesces far.
The invention provides an application of a reagent for detecting MCM6 in preparing a node outer edge zone lymphoma prognosis diagnosis kit; prognosis in application is to predict whether node outer edge zone lymphomas relapse far away.
The invention provides a diagnostic kit for prognosis of lymphoma in the outer edge zone of a junction, wherein the kit comprises a reagent for detecting MCM 6; the diagnostic kit is used for predicting whether the lymphoma in the outer edge zone of the junction recrudesces far.
The invention provides a detection system, which comprises a data processing device and a substance for detecting MCM 6; the data processing device comprises a data input module, a data recording module, a data comparison module and a conclusion output module; the data input module is configured to input the expression value of the MCM6 to be tested; the data recording module is configured to store the expression value and the judgment threshold value of the MCM6 to be tested; the data comparison module is configured to receive the expression magnitude of the MCM6 to be tested, which is sent by the data input module, and call a judgment threshold value from the data recording module and compare the judgment threshold value with the expression magnitude of the MCM6 to be tested; the conclusion output module is configured to receive the comparison result sent by the data comparison module and judge the comparison result according to a preset judgment condition; determining whether the lymphoma in the outer edge zone of the junction of the tested person recurs far. The means for detecting MCM6 includes reagents and/or instrumentation for detecting the amount of expression of MCM 6.
Examples
1. Obtaining EMZLs specific prognosis-related pathological marker MCM6:
TMT-labeled quantitative proteomic data of 27 EMZLs samples were selected for analysis, including 6 distant relapses and 21 control patients. MCM6 was screened as a protein with potential prognostic value by combining limma differential gene analysis and univariate Cox regression analysis (as shown in FIG. 1). In FIG. 1, panel A shows a flow chart of screening MCM6, and panel B shows a scatter diagram of differential gene expression.
Comparing MCM6 with Ki-67 as a predictive of distant recurrence of EMZLs-specific prognostic-related pathological markers:
2.1 comparison using H score:
44 patients with paired clinical features, including 11 distant relapses and 33 EMZL patients without distant relapses, were selected, and the prognostic value of candidate genes was verified by Immunohistochemical (IHC) staining using paraffin-embedded sections, and Ki-67 was selected as a positive control marker. Representative images of IHC staining are shown in figure 2, panel a. The overall H-score of MCM6 was significantly higher for the distant relapse group than for the control group (no relapse group) (p=0.0006). However, there was no significant difference in Ki-67 expression in the two groups (the distant relapse group and the relapse free group) (see panel B in FIG. 2). MCM6 was suggested to have potential distant recurrence prediction capability.
2.2MCM6 and Ki-67 as predictive of distant recurrence as a marker of EMZLs-specific prognosis-associated pathology:
the prognostic value of each candidate gene during the different follow-up periods was compared using time-dependent ROC curve analysis. MCM6 was more predictive of Distant Relapse Free Survival (DRFS) than Ki-67 (as shown in panel a of fig. 3).
As shown in FIG. 3B, the areas under the ROC curves (AUC values) for 1, 3, and 5 years of MCM6 were 0.735, 0.699, and 0.757, respectively, each higher than Ki-67 (0.487, 0.532, and 0.592).
Patients were divided into two groups with median marker H score as demarcation value. The KM survival curve shows that high expression of MCM6 is significantly correlated with shorter DRFS, whereas expression of Ki-67 is not significantly correlated with DRFS (log rank p=0.017, log rank p=0.18; as shown in figure 3, panel C). This suggests that MCM6 may be better predictive of distant recurrence than Ki-67.
Multifactorial Cox regression analysis demonstrated that MCM6 was an independent risk factor for distant recurrence (HR, 6.86;95%CI:1.32-35.79; p=0.02; table 1).
TABLE 1 Cox regression Risk model for distant recurrence
The results prove that MCM6 is a specific high-expression protein for EMZL distant recurrence and can be used as a pathological marker for EMZL prognosis.
The invention uses proteomics sequencing data to screen a pathological prognosis biomarker MCM6 capable of predicting distant recurrence of EMZL patients, and can be used for guiding risk stratification and treatment decision of patients.
While the invention has been described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Equivalent embodiments of the present invention will be apparent to those skilled in the art having the benefit of the teachings disclosed herein, when considered in the light of the foregoing disclosure, and without departing from the spirit and scope of the invention; meanwhile, any equivalent changes, modifications and evolution of the above embodiments according to the essential technology of the present invention still fall within the scope of the technical solution of the present invention.
Claims (8)
1. A method for obtaining prognostic information for lymphoma in the outer junction region, comprising predicting prognostic information for lymphoma in the outer junction region by detecting MCM6 expression levels.
2. The method of claim 1, wherein the prognostic information is predictive of whether a node outer border region lymphoma is distant recurrence.
3. An application of a reagent for detecting MCM6 in preparing a node outer edge zone lymphoma prognosis diagnosis kit.
4. The use of claim 3, wherein the prognosis is predicting whether a node-outside border region lymphoma is distant to relapse.
5. A diagnostic kit for prognosis of lymphoma in the outer junction edge region, comprising reagents for detecting MCM 6.
6. The diagnostic kit for the prognosis of a node-outside border region lymphoma according to claim 5, wherein said prognosis is predictive of whether node-outside border region lymphoma recurs far.
7. A detection system comprising data processing means and a substance for detecting MCM 6; the data processing device comprises a data input module, a data recording module, a data comparison module and a conclusion output module; the data input module is configured to input an expression value of a sample MCM6 to be tested; the data recording module is configured to store the expression value and the judgment threshold value of the MCM6 of the sample to be tested; the data comparison module is configured to receive the expression magnitude of the to-be-detected sample MCM6 sent by the data input module, call the judgment threshold value from the data recording module and compare the judgment threshold value with the expression magnitude of the to-be-detected sample MCM 6; the conclusion output module is configured to receive the comparison result sent by the data comparison module and judge the comparison result according to a preset judgment condition; determining whether the lymphoma in the outer edge zone of the junction of the tested person recurs far.
8. The system according to claim 7, wherein: the substance for detecting the MCM6 comprises a reagent and/or an instrument for detecting the expression quantity value of the MCM 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211579996.7A CN116008559A (en) | 2022-12-09 | 2022-12-09 | Application of MCM6 as pathological prognosis marker of EMZL distant recurrence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211579996.7A CN116008559A (en) | 2022-12-09 | 2022-12-09 | Application of MCM6 as pathological prognosis marker of EMZL distant recurrence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116008559A true CN116008559A (en) | 2023-04-25 |
Family
ID=86036363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211579996.7A Pending CN116008559A (en) | 2022-12-09 | 2022-12-09 | Application of MCM6 as pathological prognosis marker of EMZL distant recurrence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116008559A (en) |
-
2022
- 2022-12-09 CN CN202211579996.7A patent/CN116008559A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Asplund et al. | Antibodies for profiling the human proteome—The H uman P rotein A tlas as a resource for cancer research | |
| Ellis et al. | Best Practice No 176: Updated recommendations for HER2 testing in the UK | |
| Balic et al. | Circulating tumor cells: from bench to bedside | |
| JP6143743B2 (en) | Cluster analysis of biomarker expression in cells | |
| Bai et al. | An open-source, automated tumor-infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer | |
| Geradts et al. | The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features | |
| Holten-Rossing et al. | Optimizing HER2 assessment in breast cancer: application of automated image analysis | |
| Schettini et al. | A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes | |
| Ram et al. | Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images | |
| Touati et al. | CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment | |
| CN114740202A (en) | Compositions and methods relating to diagnosis of prostate cancer | |
| JP2018535433A (en) | Biomarkers for the detection of breast cancer in women with dense breast | |
| JP2017207516A (en) | Malignancy detection method and kit of peripheral circulating tumor cell unit | |
| KR20180018514A (en) | Compositions and methods for active monitoring of prostate cancer | |
| Harmon et al. | High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts | |
| US10444235B2 (en) | Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer | |
| CN112946276B (en) | Postoperative recurrence risk prediction system for stage I lung adenocarcinoma patient and application thereof | |
| Smith et al. | A comparison between high resolution serum protein electrophoresis and screening immunofixation for the detection of monoclonal gammopathies in serum | |
| Gustavson et al. | Tissue microarrays: leaping the gap between research and clinical adoption | |
| Jørgensen et al. | Untangling the intracellular signalling network in cancer—A strategy for data integration in acute myeloid leukaemia | |
| CN116008559A (en) | Application of MCM6 as pathological prognosis marker of EMZL distant recurrence | |
| Gruver et al. | Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity | |
| US20180356419A1 (en) | Biomarkers for detection of tuberculosis risk | |
| Yi et al. | Quantile Index Biomarkers Based on Single-Cell Expression Data | |
| CN113496768A (en) | Bigeminal comprehensive tumor analysis system based on pathological tissues and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |